Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Glioblastoma 527Brain Neoplasms 415Glioma 343Astrocytoma 239Central Nervous System Neoplasms 201Neuroblastoma 195Gliosarcoma 163Oligodendroglioma 149Medulloblastoma 118Neoplasms 113Ependymoma 72Recurrence 70Breast Neoplasms 69Sarcoma 65Melanoma 62Carcinoma, Non-Small-Cell Lung 58Osteosarcoma 57Diffuse Intrinsic Pontine Glioma 48Wilms Tumor 47Familial ependymoma 47Lymphoma 46Neoplasm Metastasis 45Optic Nerve Glioma 44Rhabdomyosarcoma 42Rhabdoid Tumor 42Lung Neoplasms 42Choroid Plexus Neoplasms 42Neuroectodermal Tumors, Primitive 38Meningeal Carcinomatosis 38Ovarian Neoplasms 37

Interventions

Dexamethasone 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Basophil × CNS × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡